The National Company Law Tribunal, Ahmedabad Bench, has sanctioned the scheme of amalgamation of Vitanosh Ingredients Private Limited with Lactose (India) Limited . The order, dated August 5, 2026, consolidates the operations of the two entities to enhance manufacturing scale and market access in the lactose sector.

The tribunal approved the scheme with an appointed date of October 1, 2024. Vitanosh Ingredients will be dissolved without winding up, transferring all assets, liabilities, and employees to the transferee company. Shareholders of the transferor company will receive 0.7946 equity shares of Lactose (India) for every one share held.

What the Numbers Show

The financial data reveals a significant disparity in scale between the merging entities. For FY25, Lactose (India) reported revenue from operations of ₹116.39 crore against a profit before tax of ₹6.91 crore. In contrast, Vitanosh Ingredients recorded revenue of just ₹34.68 lakh and a loss before tax of ₹23.63 lakh. This indicates the merger is primarily strategic, aimed at acquiring Vitanosh’s specialized manufacturing infrastructure rather than immediate top-line contribution.

Strategic Rationale

The amalgamation is designed to expand production capabilities and achieve economies of scale. Key operational benefits include:

• Capacity Expansion: Combined manufacturing capacity increases from 10,000 metric tonnes per annum to 15,000 metric tonnes per annum.
• Product Diversification: Integration allows for the production of both Alpha Lactose and Beta Lactose, broadening the customer base to include homeopathy and pulmonary medicine sectors.
• Time to Market: Utilizing Vitanosh’s existing facility accelerates deployment compared to building new infrastructure, which typically takes three to four years.
• Cost Synergies: Streamlined procurement and administrative functions are expected to reduce operational costs and mitigate risks associated with new plant setups.

Regulatory Compliance

The tribunal addressed several regulatory observations during the proceedings:

• Delay in Filing: The delay in filing the application beyond one year from the appointed date was condoned. The companies attributed this to procedural compliances, including obtaining no-objection letters from BSE and secured creditors.
• Accounting Adjustments: The transferor company had rectified non-provisions for gratuity liabilities for FY23-FY25 in FY26, complying with Accounting Standard-15.
• Statutory Liabilities: The transferee company undertook to preserve books of accounts and comply with all statutory laws, including income tax and GST obligations.
• Share Exchange Ratio: The ratio was determined based on valuation reports dated October 23, 2024, factoring in the market price of Lactose (India)’s shares.

Lactose (India) Limited reported a net profit of ₹236.56 lakh for the first quarter ended June 30, 2026, marking a 58% increase from ₹149.86 lakh in the same period last year. Revenue from operations rose 19% year-on-year to ₹4,696.84 lakh, reflecting stronger operational performance in its pharmaceutical segment. The Board of Directors approved the unaudited financial results on August 11, 2026, following a review by the Statutory Auditor, D M K H & Co.

The profit growth was supported by improved top-line figures, although cost of materials consumed increased significantly to ₹3,249.18 lakh compared to ₹1,563.63 lakh in Q1FY25. Despite higher input costs, the company managed to expand its pre-tax profit to ₹323.32 lakh from ₹228.87 lakh in the prior year period. Basic earnings per share (EPS) stood at ₹1.88, up from ₹1.19 in Q1FY25.

Key Financial Metrics

In a separate corporate action, the Board approved the forfeiture of 15,00,000 convertible share warrants issued on December 5, 2024. The warrants, issued at ₹174 each, expired on June 5, 2026, without exercise by the allottees. Consequently, the upfront amount of ₹652.50 lakh (representing 25% of the issue price) received during allotment has been forfeited and transferred to Capital Reserve in compliance with SEBI regulations.

What the Numbers Show

While revenue growth is robust, the sharp rise in material costs warrants attention. Cost of materials consumed more than doubled year-on-year, increasing by over 100%, which suggests potential margin pressure if input prices remain elevated. However, the company successfully passed on some of these costs or optimized other expense lines, as total expenses grew at a slower rate (17.5%) than revenue (18.7%), leading to an expansion in pre-tax profits.

The company continues to pursue strategic consolidation through its Scheme of Arrangement for merger with Vitanosh Ingredients Private Limited. The scheme was approved by shareholders at the Extraordinary General Meeting held on March 28, 2026, and is currently pending final approvals from the Securities and Exchange Board of India and the National Company Law Tribunal. No accounting effect of the merger has been recognized in the current quarter’s financials.